Bayer: 5 new Phase III drugs expected in 2015

Bayer said Tuesday that it is accelerating its pipeline and expects to have five drugs in Phase III testing in 2015. The drug maker said in a statement that the drugs will swell its oncology, cardiology and women's health list of experimental treatments.

This is in addition to working on expanding the list of indications for drugs including heart drug Xarelto, cancer medication Xofigo and eye treatment Eylea.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.